Syndrome de Down, p.2017, 2017. ,
Suivi de la personne porteuse de trisomie 21 tout au long de sa vie, 2007. ,
The challenge of Down syndrome, Trends Mol Med, vol.12, issue.10, p.16935027, 2006. ,
Down syndrome and the complexity of genome dosage imbalance, Nat Rev Genet, vol.18, issue.3, p.28029161, 2017. ,
Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome, Epilepsy Behav, vol.53, p.26558714, 2015. ,
Down syndrome-A narrative review with a focus on anatomical features, Clin. Anat, vol.29, p.26599319, 2016. ,
Trisomy 21 et cancers, Morphologie, vol.96, p.23141635, 2012. ,
Marriage and reproduction in a woman with Down syndrome, Rev Med Int Sindr Down, vol.17, issue.3, pp.39-42, 2013. ,
Primary care of children and adolescents with down syndrome: an update, Curr Probl Pediatr Adolesc Health Care, vol.38, issue.8, p.18722332, 2008. ,
DYRK1A: a potential drug target for multiple Down syndrome neuropathologies, CNS Neurol Disord Drug Targets, vol.13, issue.1, p.24152332, 2014. ,
Contribution à l'étude chimique et pharmacochimique de dérivés mono-bi-et tricycliques de pyridazines, 2014. ,
Hematological disorders and leukemia in children with Down syndrome, Eur J Pediatr, vol.171, issue.9, p.22113227, 2012. ,
Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications, Antioxid Redox Signal, vol.17, issue.11, p.22115501, 2012. ,
Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome, Arch Med Res, vol.43, issue.8, p.23142525, 2012. ,
Les complications neurologiques liées à la trisomie 21, Arch Pediatr, vol.15, issue.4, p.18329863, 2008. ,
Pathophysiology of increased fetal nuchal translucency thickness, Taiwan J Obstet Gynecol, vol.49, issue.2, p.20708516, 2010. ,
Dissecting Alzheimer disease in Down syndrome using mouse models, Front Behav Neurosci, vol.9, p.26528151, 2015. ,
, Information destinée aux femmes enceintes sur la possibilité de recourir, à leur demande, au dépistage prénatal de la trisomie 21, Collège National des Gynécologues et Obstétriciens Français (CNGOF), p.2017, 2014.
The complex relationship between folate/homocysteine metabolism and risk of Down syndrome, Mutat Res, vol.682, issue.1, 2009. ,
The genetics of folate metabolism and maternal risk of birth of a child with Down syndrome and associated congenital heart defects, Front Genet, vol.6, p.26161087, 2015. ,
Risk factors for Down syndrome, Arch Toxicol, p.27600794, 2016. ,
On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome, Dev Neurosci, vol.33, issue.5, p.21893967, 2011. ,
Prospects for Improving Brain Function in Individuals with Down Syndrome, CNS Drugs, vol.27, issue.9, p.23821040, 2013. ,
From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome, Neural Plast, vol.101542, p.22848844, 2012. ,
Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome, Prog Neuropsychopharmacol Biol Psychiatry, vol.54, p.24842803, 2014. ,
Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome, Neurosci Biobehav Rev, vol.45, p.24858130, 2014. ,
Developmental defects in trisomy 21 and mouse models, ScientificWorldJournal, vol.6, p.17205199, 2006. ,
Syndrome de Down-Nouvelles perspectives the?rapeutiques ?, Med Sci (Paris), vol.26, issue.4, p.20412741, 2010. ,
Inherited aneuploidy: germline mosaicism, Cytogenet Genome Res, vol.133, issue.24, p.21487228, 2011. ,
The ?7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome, Biochem Pharmacol, vol.97, issue.4, p.26074265, 2015. ,
Murine models for Down syndrome, Physiol Behav, vol.73, issue.5, p.11566219, 2001. ,
Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments, Behav Genet, vol.36, issue.3, p.16520905, 2006. ,
Down Syndrome: From Understanding the Neurobiology to Therapy, Prog Brain Res, vol.197, 2012. ,
Human Evolution, Morphological Variations and Defects, and Medicine, Evolutionary Developmental Pathology and Anthropology: A New Field Linking Development, Comparative Anatomy, vol.244, p.26293597, 2015. ,
De?pistage non invasif de la Trisomie 21: entre chime?re et re?alite?. Mémoire SagesFemmes, 2014. ,
Human male infertility: chromosome anomalies, meiotic disorders, abnormal spermatozoa and recurrent abortion, Hum Reprod Update, vol.6, issue.1, p.10711834, 2000. ,
Regulation of the MIR155 host gene in physiological and pathological processes, Gene, vol.532, issue.1, p.23246696, 2013. ,
Molecular changes in fetal Down syndrome brain, J Neurochem, vol.84, issue.5, p.12603815, 2003. ,
Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones, Am J Kidney Dis, vol.67, issue.3, p.26463139, 2016. ,
, , p.2017
Is there a paternal age effect for aneuploidy?, Cytogenet Genome Res, vol.133, issue.2-4, p.21212646, 2011. ,
Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome, J Neurosci, vol.35, issue.4, p.4308587, 2015. ,
On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models, Brain Res Brain Res Rev, vol.35, issue.2, p.11336779, 2001. ,
Memory and learning-using mouse to model neurobiological and behavioural aspects of Down syndrome and assess pharmacotherapeutics. Down Syndrome Research and Practice (Online), 2008. ,
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations, Drug Des Devel Ther, vol.9, p.25552901, 2015. ,
Alterations of brain circuits in Down syndrome murine models, J Chem Neuroanat, vol.42, issue.4, p.21946025, 2011. ,
Trisomy 21 and early brain development, Trends Neurosci, vol.35, issue.2, p.22169531, 2011. ,
Meiosis and maternal aging: insights from aneuploid oocytes and trisomy births, Cold Spring Harb Perspect Biol, vol.7, issue.4, 2015. ,
Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells, J Clin Med, vol.4, issue.4, p.26239351, 2015. ,
On the origin of the maternal age effect in trisomy 21 Down syndrome: the Oocyte Mosaicism Selection model, Reproduction, vol.139, issue.1, p.19755486, 2010. ,
On the paternal origin of trisomy 21 Down syndrome, Mol Cytogenet, vol.3, p.20178584, 2010. ,
Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome, Trends Pharmacol Sci, vol.35, issue.7, p.24962069, 2014. ,
Meiosis in oocytes: predisposition to aneuploidy and its increased incidence with age, Hum Reprod Update, vol.14, issue.2, p.18084010, 2008. ,
Gene-dosage effect on chromosome 21 transcriptome in trisomy 21: implication in Down syndrome cognitive disorders, Behav Genet, vol.36, issue.3, p.16557362, 2006. ,
Down syndrome and mouse models, Curr Opin Genet Dev, vol.8, issue.3, p.9690992, 1998. ,
Germ-line transmission of trisomy 21: Data from 80 families suggest an implication of grandmaternal age and a high frequency of female-specific trisomy rescue, Mol Cytogenet, vol.3, p.20298592, 2010. ,
Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains, J Biol Chem, vol.285, issue.2, pp.1529-1572, 2010. ,
Molecular basis of maternal age-related increase in oocyte aneuploidy, Congenit Anom (Kyoto), vol.52, issue.1, p.22348779, 2012. ,
Association between maternal age and meiotic recombination for trisomy 21, Am J Hum Genet, vol.76, issue.1, p.15551222, 2005. ,
Inhibins and activins in human fetal abnormalities, Mol Cell Endocrinol, vol.225, issue.1-2, p.15451574, 2004. ,
Down syndrome: searching for the genetic culprits, Dis Model Mech, vol.4, issue.5, p.21878459, 2011. ,
Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome, 2015. ,
, Neurosci Lett, vol.591, p.25668489
Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain, Neural Plast, vol.PMID, p.26881131, 2016. ,
Preoperative evaluation and comprehensive risk assessment for children with Down syndrome, Paediatr Anaesth, vol.26, issue.4, p.26749540, 2016. ,
Reverse engineering human neurodegenerative disease using pluripotent stem cell technology, Brain Res. 1638(Pt A, vol.PMID, p.26423934, 2016. ,
Down syndrome and Alzheimer's disease: a link between development and aging, Ment Retard Dev Disabil Res Rev, vol.7, issue.3, p.11553933, 2001. ,
Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of Down syndrome, PLoS One, vol.9, issue.12, 2014. ,
Intersectin 1: a molecular linker in the central nervous system, Neurosci Bull, vol.24, issue.6, p.19037327, 2008. ,
The cognitive phenotype of Down syndrome: insights from intracellular network analysis, NeuroRx, vol.3, issue.3, p.16815222, 2006. ,
Trisomy 21-affected placentas highlight prerequisite factors for human trophoblast fusion and differentiation, Int J Dev Biol, vol.54, issue.2-3, pp.475-82, 2010. ,
Meiotic errors in human oogenesis and spermatogenesis, Reprod Biomed Online, vol.16, issue.4, p.18413061, 2008. ,
DOI : 10.1016/s1472-6483(10)60459-2
Evidence of Selection against Complex Mitotic-Origin Aneuploidy during Preimplantation Development, PLoS Genet, vol.11, issue.10, 2015. ,
Epigenomic engineering for Down syndrome, Neurosci Biobehav Rev, vol.71, pp.323-330, 2016. ,
DOI : 10.1016/j.neubiorev.2016.09.012
Susceptibility to aneuploidy in young mothers of Down syndrome children, ScientificWorldJournal, vol.9, 2009. ,
Down syndrome and the enteric nervous system, Pediatr Surg Int, vol.24, issue.8, p.18633623, 2008. ,
DOI : 10.1007/s00383-008-2188-7
Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: implications for Down syndrome, Neurobiol Dis, vol.63, p.24291518, 2014. ,
DOI : 10.1016/j.nbd.2013.11.016
URL : https://hal.archives-ouvertes.fr/hal-01179506
Do antioxidants play a role in therapy?, Physiol Res, vol.63, issue.5, p.24908086, 2014. ,
The anatomy of nuchal translucency at 10-14 weeks gestation in fetuses with trisomy 21: An incredible medical mystery, Clin Anat, vol.27, issue.3, p.24488865, 2014. ,
Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome, Am J Hum Genet, vol.83, issue.4, p.18940310, 2008. ,
Mosaicism for trisomy 21: a review, Am J Med Genet A, vol.167, issue.1, p.25412855, 2015. ,
DOI : 10.1002/ajmg.a.36861
New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome, Exp Neurobiol, vol.22, issue.4, p.24465139, 2013. ,
Genetic mechanisms involved in the phenotype of Down syndrome, Ment Retard Dev Disabil Res Rev, vol.13, issue.3, p.17910086, 2007. ,
Nondisjunction in trisomy 21: origin and mechanisms, Cytogenet Cell Genet, vol.91, issue.1-4, p.11173856, 2000. ,
DOI : 10.1159/000056844
Review: Human trophoblast fusion and differentiation: lessons from trisomy 21 placenta, Placenta, vol.33, p.22138060, 2012. ,
DOI : 10.1016/j.placenta.2011.11.007
Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms, Neurosci Res, vol.59, issue.4, p.17897742, 2007. ,
DOI : 10.1016/j.neures.2007.08.007
Mouse models of cognitive disabilities in trisomy 21 (Down syndrome), Am J Med Genet C Semin Med Genet, vol.154, issue.4, p.20981769, 2010. ,
DOI : 10.1002/ajmg.c.30280
URL : https://hal.archives-ouvertes.fr/hal-00550504
Using mouse models to explore genotypephenotype relationship in Down syndrome, Ment Retard Dev Disabil Res Rev, vol.13, issue.3, p.17910089, 2007. ,
DOI : 10.1002/mrdd.20164
Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome, Sci Transl Med, vol.1, issue.7, p.20368182, 2009. ,
Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1, Nat Commun, vol.6, p.26310823, 2015. ,
Acute leukemias in children with Down syndrome, Mol Genet Metab, vol.107, issue.1-2, p.22867885, 2012. ,
Mouse models of cognitive disorders in trisomy 21: a review, Behav Genet, vol.36, issue.3, p.16523244, 2006. ,
Risk factors for nondisjunction of trisomy 21, Cytogenet Genome Res, vol.111, issue.3-4, p.16192705, 2005. ,
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials, Front Psychol, vol.6, p.26089807, 2015. ,
Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models, Front Behav Neurosci, vol.9, p.26539088, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01263753
Timing of therapies for Down syndrome: the sooner, the better, Front Behav Neurosci, vol.9, p.26500515, 2015. ,
Tumorigenesis and neurodegeneration: two sides of the same coin?, Bioessays, vol.30, issue.8, p.18623069, 2008. ,
Trisomie 21 : 50 ans entre me?decine et science, Med Sci (Paris), vol.26, issue.3, p.20346276, 2010. ,
Proble?mes pose?s par les maladies ge?ne?tiques, 3e partie-A? propos d'une maladie chromosomique : la trisomie 21, Rev Prat, vol.54, issue.12, p.15461058, 2004. ,
Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis, J Neuroinflammation, vol.10, p.23866266, 2013. ,
Down syndrome-recent progress and future prospects, Hum Mol Genet, vol.18, issue.R1, p.19297404, 2009. ,
Atypical aging in Down syndrome, Dev Disabil Res Rev, vol.18, issue.1, pp.51-67, 2013. ,